The HPV-negative/p53 mutant cohort, accounting for 15% of VSCC, has the worst survival and tends to recur more often compared to the HPV-negative/p53 wild-type VSCC cohort, accounting for 66% of vulvar cancers in this study [8]. Here, TP53 is linked to vulva cancer.